Selecting and screening recombinant antibody libraries

During the past decade several display methods and other library screening techniques have been developed for isolating monoclonal antibodies (mAbs) from large collections of recombinant antibody fragments. These technologies are now widely exploited to build human antibodies with high affinity and...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2005-09, Vol.23 (9), p.1105-1116
Main Author: Hoogenboom, Hennie R
Format: Article
Language:English
Subjects:
Adalimumab
Affinity
Agriculture
Animals
Antibodies
Antibodies - chemistry
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized
Antibody libraries
Automation
Bacteria - metabolism
Binding Sites
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biophysics - methods
Biotechnology
Clinical trials
Directed evolution
Enzyme-Linked Immunosorbent Assay
Humans
Immunization
Immunoglobulin Fragments - chemistry
Immunoglobulin G
Libraries
Life Sciences
Monoclonal antibodies
Mutagenesis
Peptide Library
Reagents
Recombinant Proteins - chemistry
review-article
Ribosomes - chemistry
RNA, Messenger - metabolism
Saccharomyces cerevisiae - metabolism
Screening
Therapeutic targets
Tumor necrosis factor
Tumor Necrosis Factor-alpha - chemistry
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the past decade several display methods and other library screening techniques have been developed for isolating monoclonal antibodies (mAbs) from large collections of recombinant antibody fragments. These technologies are now widely exploited to build human antibodies with high affinity and specificity. Clever antibody library designs and selection concepts are now able to identify mAb leads with virtually any specificity. Innovative strategies enable directed evolution of binding sites with ultra-high affinity, high stability and increased potency, sometimes to a level that cannot be achieved by immunization. Automation of the technology is making it possible to identify hundreds of different antibody leads to a single therapeutic target. With the first antibody of this new generation, adalimumab (Humira, a human IgG1 specific for human tumor necrosis factor (TNF)), already approved for therapy and with many more in clinical trials, these recombinant antibody technologies will provide a solid basis for the discovery of antibody-based biopharmaceuticals, diagnostics and research reagents for decades to come.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt1126